EUVIMEDEUVIMED entdecken
Crossref

A high‐fidelity, dual site‐specific integration system in CHO cells by a Bxb1 recombinase

Yifeng Xu iD, Kerstin B Crowe, Paulena L Lieske, Michael Barnes, Kalpanie Bandara, Jianlin Chu, Wei Wei iD, John J Scarcelli, Lin Zhang

Biotechnology Journal · 2024

DOI: 10.1002/biot.202300410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Yifeng Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Science, Pfizer Inc, Andover, Massachusetts, USA. Hauptthemen laut MEDLINE: Recombinases, Genomics. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Pfizer, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Site‐specific integration (SSI) via recombinase mediated cassette exchange (RMCE) has shown advantages over random integration methods for expression of biotherapeutics. As an extension of our previous work developing SSI host cells, we developed a dual‐site SSI system having two independent integration sites at different genomic loci, each containing a unique landing pad (LP). This system was leveraged to generate and compare two RMCE hosts, one (dFRT) compatible with the Flp recombinase, the other (dBxb1) compatible with the Bxb1 recombinase. Our comparison demonstrated that the dBxb1 host was able to generate stable transfectant pools in a shorter time frame, and cells within the dBxb1 transfectant pools were more phenotypically and genotypically stable. We further improved process performance of the dBxb1 host, resulting in desired fed batch performance attributes. Clones derived from this improved host (referred as 41L‐11) maintained stable expression profiles over extended generations. While the data represents a significant improvement in the efficiency of our cell line development process, the dual LP architecture also affords a high degree of flexibility for development of complex protein modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RecombinasesGenomicsCricetinaeAnimalsCHO CellsCricetulusClone CellsTransgenes

Stichwörter der Autor:innen

Bxb1FRTRMCEcell line developmentmonoclonal antibodysite-specific Integration

Substanzen

Recombinases

Autor:innen und Institutionen

  • Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Science, Pfizer Inc, Andover, Massachusetts, USA.

ORCID-Profile: Yifeng Xu, Wei Wei

Förderung

  • Pfizer, Inc.

Zitieren

APA

Xu, Y., Crowe, K. B., Lieske, P. L., Barnes, M., Bandara, K., Chu, J., Wei, W., Scarcelli, J. J., & Zhang, L. (2024). A high‐fidelity, dual site‐specific integration system in CHO cells by a Bxb1 recombinase. Biotechnology Journal. https://doi.org/10.1002/biot.202300410

Vancouver

Xu Y, Crowe KB, Lieske PL, Barnes M, Bandara K, Chu J, et al. A high‐fidelity, dual site‐specific integration system in CHO cells by a Bxb1 recombinase. Biotechnology Journal. 2024. doi:10.1002/biot.202300410

BibTeX
@article{Xu2024,
  author = {Xu, Yifeng and Crowe, Kerstin B and Lieske, Paulena L and Barnes, Michael and Bandara, Kalpanie and Chu, Jianlin and Wei, Wei and Scarcelli, John J and Zhang, Lin},
  title = {A high‐fidelity, dual site‐specific integration system in CHO cells by a Bxb1 recombinase},
  journal = {Biotechnology Journal},
  year = {2024},
  doi = {10.1002/biot.202300410}
}
Kostenlos starten →